Investigational Drug Information for VTP-27999
✉ Email this page to a colleague
What is the development status for investigational drug VTP-27999?
VTP-27999 is an investigational drug.
There have been 18 clinical trials for VTP-27999.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 21st 2019.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Psoriasis, and Kidney Neoplasms. The leading clinical trial sponsors are Steba Biotech S.A., Vitae Pharmaceuticals, Inc., and Vitae Pharmaceuticals Inc., an Allergan affiliate.
There are fourteen US patents protecting this investigational drug and one hundred and thirty-five international patents.
Summary for VTP-27999
| US Patents | 14 |
| International Patents | 135 |
| US Patent Applications | 34 |
| WIPO Patent Applications | 9 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 3 (2019-01-21) |
| Vendors | 36 |
Recent Clinical Trials for VTP-27999
| Title | Sponsor | Phase |
|---|---|---|
| ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study | ICON plc | Phase 3 |
| ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study | Medpace, Inc. | Phase 3 |
| ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study | PrimeVigilance | Phase 3 |
Clinical Trial Summary for VTP-27999
Top disease conditions for VTP-27999
Top clinical trial sponsors for VTP-27999
US Patents for VTP-27999
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| VTP-27999 | See Plans and Pricing | sGC stimulators | Ironwood Pharmaceuticals, Inc. (Cambridge, MA) | See Plans and Pricing |
| VTP-27999 | See Plans and Pricing | sGC stimulators | Ironwood Pharmaceuticals, Inc. (Cambridge, MA) | See Plans and Pricing |
| VTP-27999 | See Plans and Pricing | sGC stimulators | Cyclerion Therapeutics, Inc. (Cambridge, MA) | See Plans and Pricing |
| VTP-27999 | See Plans and Pricing | sGC stimulators | Cyclerion Therapeutics, Inc. (Cambridge, MA) | See Plans and Pricing |
| VTP-27999 | See Plans and Pricing | sGC stimulators | Cyclerion Therapeutics, Inc. (Cambridge, MA) | See Plans and Pricing |
| VTP-27999 | See Plans and Pricing | Piperidine renin inhibitors | Vitae Pharmaceuticals, Inc. (Fort Washington, PA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for VTP-27999
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| VTP-27999 | Australia | AU2015317818 | 2034-09-17 | See Plans and Pricing |
| VTP-27999 | Brazil | BR112017005248 | 2034-09-17 | See Plans and Pricing |
| VTP-27999 | Canada | CA2961531 | 2034-09-17 | See Plans and Pricing |
| VTP-27999 | China | CN107223125 | 2034-09-17 | See Plans and Pricing |
| VTP-27999 | Eurasian Patent Organization | EA201790627 | 2034-09-17 | See Plans and Pricing |
| VTP-27999 | European Patent Office | EP3194395 | 2034-09-17 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
